Our Caregiver Resource page has information and resources to help and support caregivers in the SCD community. Check it out here:

Caregiver Resources

SCD Treatments

Home / Blog / SCD Treatments

In July 2017, The U.S. Food and Drug Administration (FDA) approved the first sickle cell treatment in nearly 20 years. The treatment, Endari®, was created to help reduce complications associated with sickle cell disease (SCD). In late 2019- just over two years later- the FDA would approve two more drugs: Oxbryta™ and Adakveo®. 

The following is a collection of information about the FDA approved sickle cell treatments Endari®, Oxbryta™ and Adakveo®. 

Endari®

Endari® was approved by the FDA for patients five and older on July 7, 2017. The treatment is used to reduce severe complications associated with SCD (e.g., acute chest syndrome).

Endari®, which is an oral L-glutamine powder, works by increasing the amount of free glutamine circulating in the blood. This glutamine is taken up by sickle cells (i.e., red blood cells that have sickled due to oxidation damage) to create anti-oxidant molecules as a product of glutamine degradation. The presence of the newly created antioxidants help neutralize the sickled red blood cells, so they can regain flexibility and properly travel through vessels without slowing blood flow and successfully carry oxygen throughout the body. 

Oxbryta™

Oxbryta™ (voxelotor) was approved by the FDA for patients 12 and older on November 25, 2019. The first-of-its-kind treatment targets the fundamental cause of SCD by helping to stop the sickling of red blood cells (polymerization) and increasing the number of healthy cells properly carrying oxygen throughout the body.

By increasing the oxygen affinity for hemoglobin, Oxbryta™ stabilizes red blood cells which prevents them from becoming sickled. Healthy red blood cells, unlike those that are sickled, can maintain normal blood flow and oxygen throughout the body. 

Adakveo®

Adakveo® (crizanlizumab) was approved by the FDA for patients 16 and older on November 15, 2019. The treatment is used to help reduce the number of sickle cell crises (i.e., vaso-occlusive crises) in patients.

The drug attaches to P-selection which contributes to the “stickiness” that occurs in sickled red blood cells to prevent it from connecting to healthy cells. By preventing the adhesion of sickle cells to blood vessels, healthy cells can maintain normal blood flow. 

 

Reach out to your healthcare providers to learn more about these treatments and to see if they’re right for you. 

For additional information on these FDA-approved drugs, please visit dailymed.nlm.nih.gov/dailymed.

 

This content on the Sick Cells blog and all other content and web pages associated with Sick Cells is meant strictly for informational purposes only.  This site is not a substitute for professional medical advice, diagnosis, or treatment advice from a medical professional. No information or content appearing here constitutes medical or other professional advice. 

Sick Cell does not recommend or endorse any specific products, procedures, medications, treatments processes, or services.  Reference to any products, procedures, medications, treatments processes, or services does not constitute or imply its endorsement, recommendation, or favoring by Sick Cells. The appearance of any external hyperlinks does not constitute endorsement by the Sick Cells of the linked websites, organizations, information, products, or services contained therein.

Consult your doctor before making any changes to your treatment.  Never disregard professional medical advice or delay in seeking treatment because of something you have read or seen on the Sick Cells website.  

Stay in the Know

Sign up for our newsletter!